IVF PulseFree Second Opinion

Preimplantation genetic testing for aneuploidy (PGT-A)

Should you do PGT-A after a failed IVF cycle?

The short answer

For most people, PGT-A does not raise the chance of a baby from a cycle. In a trial of women aged 20–37 with three or more good blastocysts, live birth was 77.2% with testing and 81.8% without 5. It does lower miscarriage 1. For older women, repeated losses or repeated failures the evidence is weaker and mostly observational 1,8.

After a failed cycle, PGT-A is often the first add-on suggested: test the embryos, transfer only the normal ones, and avoid another wasted transfer. The logic is appealing, and part of it is true. A euploid embryo is more likely to implant than an untested one.

What the logic leaves out is that PGT-A does not make any embryo better. It only sorts the ones you already have, and it can discard some that would have become babies 1,3. This page sets out who the trials say it may help and who it doesn't, compares transferring untested embryos with testing them, and covers mosaic results and what testing costs you in embryos. It replaces our earlier article on PGT-A and keeps the sources from it that still hold.

Reading your report

PGT-A
A few cells are taken from the outer layer of a day 5–7 blastocyst and checked for the number of chromosomes. The embryo is usually frozen while the result is awaited 1,2.
Euploid
The biopsy showed the expected 46 chromosomes. It raises the chance per transfer but does not settle it.
Aneuploid
Extra or missing chromosomes in the biopsy. The HFEA notes these embryos have less chance of developing into a baby 1.
Mosaic (low-level / high-level)
The biopsy suggests a mix of normal and abnormal cells. ASRM notes that an 'intermediate' result can also come from testing artefacts such as amplification bias, contamination or biopsy technique 3.
Segmental
Part of a chromosome, rather than a whole one, appears extra or missing. ASRM asks clinics to have a written policy on these and on mosaic results before testing 3.
No result
The lab could not read the biopsy. ASRM lists this among outcomes to discuss before testing 3.
PGT-M / PGT-SR
Different tests: PGT-M checks for a known single-gene condition in the family, PGT-SR for a known chromosomal rearrangement in a parent. ESHRE recommends genetic counselling and PGT where relevant if a parent carries a chromosomal abnormality 7.

Does PGT-A improve the chance of a baby?

Not per started cycle, in the trials so far. The STAR trial randomised 661 women aged 25–40 with at least two blastocysts that could be biopsied. Ongoing pregnancy per woman randomised was 41.8% with PGT-A and 43.5% without 4. A Chinese trial of 1,212 women aged 20–37 with three or more good blastocysts found cumulative live birth of 77.2% with PGT-A and 81.8% with conventional IVF 5.

A 2020 Cochrane review of 13 trials with 2,794 women found insufficient good-quality evidence of a difference in cumulative live birth, live birth after the first transfer or miscarriage 6. ASRM's 2024 committee opinion states that the value of PGT-A as a routine screening test for all IVF patients has not been demonstrated 3. ESHRE's 2023 add-ons recommendations do not recommend it for routine use 2, and the HFEA rates it red for the chance of a baby for most patients 1.

The reason is not that the test fails to find abnormal embryos. It is that sorting cannot add embryos. The HFEA explains the red rating by noting that PGT-A often reduces the number of embryos available for transfer, and that time to a live birth may be longer 1.

Then why do clinics say PGT-A works?

Because per transfer, a tested embryo does look better. In STAR, ongoing pregnancy per transfer was 50% with PGT-A and 46% without, a difference that was not statistically significant 4. The HFEA rates PGT-A green for reducing miscarriage for most patients 1. In the Chinese trial, clinical pregnancy loss was 8.7% with PGT-A and 12.6% without 5.

Per transfer and per cycle are different questions. Fewer transfers and fewer miscarriages are real benefits, and for some people they matter a great deal. They are not the same as more babies. The HFEA adds that its green rating rests on secondary outcomes in trials not designed to measure miscarriage, and that a lower miscarriage rate may not increase the chance of having a baby 1.

Both big trials have critics. ESHRE notes that STAR randomised only women with two or more blastocysts, and that the Chinese trial did not transfer mosaic embryos 2. STAR also excluded women over 40 and those with multiple miscarriages or multiple IVF failures 3, which is exactly the group this page is written for.

Does PGT-A help older women?

Possibly, but the evidence is thinner than the marketing. The HFEA rates PGT-A grey for older women, meaning there is not enough moderate or high-quality evidence to rate it either way 1. In STAR, a post hoc analysis of women aged 35–40 found ongoing pregnancy per transfer of 51% with PGT-A and 37% without, but no difference per woman randomised 4. ESHRE notes that claims of benefit in older women rest on post hoc analyses that need confirming 2.

In a trial of women aged 38–41, PGT-A meant fewer transfers per live birth (1.8 versus 3.7) and fewer miscarriages (2.7% versus 39.0%), but no significant difference in cumulative delivery per woman 11. That trial biopsied embryos on day 3, an older method 11. ASRM concludes that PGT-A may have a beneficial role for older women, especially those with good ovarian reserve 3.

Age also raises the chance that no embryo is normal. In 15,169 US embryo biopsies, the share of women with no euploid embryo was 2–6% at ages 26–37, 33% at 42 and 53% at 44 15. For some older women, PGT-A mainly answers the question of whether any embryo is transferable, at the cost of a cycle with nothing to transfer.

What if I have had repeated failed transfers or miscarriages?

After repeated failed transfers, ESHRE's 2023 recommendations say PGT-A can be considered 7. ASRM's 2026 opinion says it can be offered with untested embryos, in shared decision-making, to see whether embryo chromosomes explain the failures, but states there is no evidence that PGT-A increases the chance of live birth in RIF 8.

A 2026 meta-analysis of 13 studies in women with repeated implantation failure found higher cumulative live birth with PGT-A (odds ratio 4.23 across four studies) 12. All 13 studies were observational, most retrospective, and the authors warn of a high risk of selection bias and call for randomised trials before practice changes 12. The older randomised trials in this group, which used earlier methods, found no improvement 7.

After repeated miscarriages, the HFEA notes evidence that PGT-A may reduce miscarriage, particularly in older women or women with a history of miscarriage, but that this comes from secondary outcomes 1. ESHRE's 2022 pregnancy-loss guideline describes the evidence for preimplantation genetic testing in recurrent pregnancy loss as very low quality, showing no clear benefit 13. ASRM cites one cohort in which the time to pregnancy was longer with PGT-A than with expectant management, meaning trying without IVF (6.5 versus 3.0 months) 3.

What does PGT-A cost in embryos?

Every test result that stops a transfer is a trade. In STAR, 274 of 330 women in the PGT-A group reached a transfer, against 313 of 331 without testing 4. The HFEA warns that an inaccurate result can mean healthy embryos are discarded, that some embryos are not suitable for biopsy, and that sometimes no embryo is suitable to transfer 1.

ASRM describes a retrospective study in which about 1 in 6 embryos (17.1%) that had already led to healthy births would have been discarded as mosaic or falsely abnormal if PGT-A had been used, while cautioning that the study's methods may have affected that figure 3. ESHRE notes differences in mosaic diagnosis between laboratories, and a possible small increase in fetal growth restriction after biopsy that needs larger studies 2.

Rupee costs vary by clinic and lab, and we could not find a published, verifiable figure for India. Ask your clinic for the full cost, including biopsy, freezing and each frozen transfer.

What if an embryo comes back mosaic?

Do not assume it is abnormal, and do not assume it is normal. ASRM states that mosaic embryos can implant and produce apparently euploid babies, though they may implant at a lower rate 3. In a double-blind trial where results were hidden until after birth, live-birth and miscarriage rates were similar across 484 euploid, 282 low-grade mosaic and 131 medium-grade mosaic embryos 9.

A pooled analysis of 1,000 mosaic transfers found lower ongoing pregnancy or birth than euploid transfers (37.0% versus 52.3%) and more miscarriage (20.4% versus 8.6%), with outcomes worse at higher mosaic levels 10. In the Chinese PGT-A trial, 11.7% of tested embryos were mosaic and none were transferred 3.

ASRM advises clinics to disclose a written policy on mosaic and segmental results before testing, and to make genetic counselling available at any point 3. Ask for that policy before the biopsy, not after.

Is PGT-A allowed in India, and what can it not be used for?

India's ART (Regulation) Act 2021, section 25, says preimplantation genetic testing shall be used to screen embryos for known, pre-existing, heritable or genetic diseases only 14. How that wording applies to routine aneuploidy screening is a question to put to your clinic, and to ask how they document the reason for testing.

PGT-A must never be used to choose or learn an embryo's sex. Section 26 of the same Act forbids clinics from offering a child of a pre-determined sex, subject to the PC&PNDT Act 1994, and forbids any act to identify the sex of an embryo except to diagnose a sex-linked disease 14.

It depends on…

How old were you when the eggs were collected?

Under 35

The trials show no gain in babies per cycle. In women aged 20–37 with three or more good blastocysts, live birth was 77.2% with PGT-A and 81.8% without 5.

35 to 40

Possibly fewer transfers: 51% vs 37% ongoing pregnancy per transfer in STAR's post hoc analysis, but no difference per woman 4. ESHRE says this needs confirming 2.

Over 40

HFEA: grey for older women, not enough evidence to rate 1. In women aged 38–41, fewer transfers and miscarriages but similar cumulative delivery 11. Higher chance of no euploid embryo at all 15.

How many blastocysts does a cycle usually give you?

One or none

Little to choose between. The HFEA notes testing may leave no embryo suitable for transfer 1. Discuss whether to transfer untested.

Two

This was the STAR population: per woman, 41.8% ongoing pregnancy with PGT-A versus 43.5% without 4.

Three or more

No more babies per cycle in the Chinese trial, but fewer clinical pregnancy losses: 8.7% vs 12.6% 5.

What has happened in your previous cycles?

One failed transfer of an untested embryo

Chance is the likelier explanation. ESHRE suggests proceeding with another transfer until your cumulative predicted chance passes 60% 7.

Repeated failed transfers of good embryos

ESHRE: PGT-A can be considered 7. ASRM: can be offered to explore the cause, with no evidence it raises live birth in RIF 8.

Two or more miscarriages

HFEA: may reduce miscarriage, from secondary outcomes 1. ESHRE rates the evidence in recurrent loss as very low quality, with no clear benefit 13.

A parent carries a known chromosomal rearrangement or genetic condition

That calls for genetic counselling and PGT-SR or PGT-M, which are different tests 7.

Transferring untested embryos vs PGT-A

Untested embryos, transferred one by onePGT-A, euploid embryos only
Live birth per started cycle (women 20–37, 3+ good blastocysts)81.8% 577.2% 5
Ongoing pregnancy per woman (STAR, ages 25–40)43.5% 441.8% 4
Ongoing pregnancy per transfer (STAR)46% 450% 4
Clinical pregnancy loss (women 20–37)12.6% 58.7% 5
Women reaching a transfer (STAR)313 of 331 4274 of 330 4
Transfers per live birth (women 38–41, day-3 biopsy)3.7 111.8 11
Embryos that may be lostNone to testingSome viable embryos discarded as mosaic or falsely abnormal 1,3
Extra stepsNone beyond usual careBiopsy, freezing all embryos, waiting for results 1,2
HFEA rating for most patientsRoutine proven treatment 1Red for chance of a baby; green for miscarriage 1

What's worth checking

  • Write down your age at egg collection and how many blastocysts each cycle produced.
  • Ask what your clinic would do if no embryo came back euploid.
  • Ask for the lab's written policy on mosaic, segmental and no-result embryos before testing 3.
  • Ask whether genetic counselling is available before and after the result 3.
  • Ask for the full cost: biopsy, lab fee per embryo, freezing, storage and each frozen transfer.
  • Ask how the clinic applies section 25 of the ART Act to aneuploidy screening 14.

Questions to ask your doctor

  1. Given my age and embryo numbers, what do you expect PGT-A to change: my chance of a baby, the number of transfers, or my miscarriage risk?
  2. What is your lab's euploid rate for women my age, and how often do patients like me end up with no embryo to transfer?
  3. What is your policy on mosaic and segmental results, and will you transfer a mosaic embryo if it is all I have 3?
  4. Which genetics lab analyses the biopsy, and what is its rate of no-result biopsies?
  5. If I don't test, how would you choose which embryo to transfer first?
  6. How do you document the reason for PGT under section 25 of the ART Act 14?

Questions people ask

Is PGT-A worth it after one failed IVF cycle?

Usually not on that basis alone. One failed transfer of an untested embryo is common, and ESHRE suggests simply proceeding with another transfer until your cumulative predicted chance of implantation passes 60% 7. For most patients the HFEA rates PGT-A red for the chance of a baby 1.

Does a normal PGT-A result mean I will get pregnant?

No. In STAR, half of transfers of euploid embryos led to an ongoing pregnancy 4. The HFEA notes that the test can occasionally miss an abnormality or report one that isn't there 1.

Can the biopsy damage the embryo?

The HFEA says embryos can continue to develop after a careful biopsy, but lists risks to the embryo including inaccurate results 1. ESHRE notes no adverse obstetric outcomes in follow-up so far, with a possible small increase in fetal growth restriction that needs larger studies 2.

Can I test embryos that are already frozen?

ASRM describes studies where frozen, untested embryos were warmed, biopsied and refrozen, with a lower survival rate on the second warming in one study (87.5% versus 98.3%) 3. Ask your lab about its own results before deciding.

What happens if none of my embryos come back normal?

There is no transfer that cycle. The HFEA lists this as a known outcome of testing: no embryo may be suitable if abnormalities are found in all of those tested 1. How likely that is depends mostly on age — in 15,169 US biopsies, the share of women with no euploid embryo was 2–6% at ages 26–37, 33% at 42 and 53% at 44 15. What follows is another collection, or your clinic's mosaic policy 3.

Does PGT-A check for Down syndrome or for conditions like thalassaemia?

PGT-A counts chromosomes, so it looks for embryos with missing or extra chromosomes 1 — the group that includes trisomy 21. It does not test for single-gene conditions such as thalassaemia; that is PGT-M, a separate test, and ESHRE recommends genetic counselling where a known condition runs in the family 7. India's ART Act allows testing to screen for known, pre-existing, heritable or genetic diseases 14.

What does a 'no result' embryo mean, and can it be tested again?

It means the lab could not read the biopsy. ASRM reports an inconclusive result in 0.86% to 3.8% of biopsies, and says re-biopsy means warming the embryo, taking a second sample and freezing it again 3. The data on doing that are mixed: in one cohort, clinical pregnancy was 44% after two freezes with a single biopsy against 46% with one of each 3.

Is PGT-A worth doing when the eggs come from a donor?

The evidence is thin and does not show a gain. ASRM describes a cohort of 31 donor-egg cycles with PGT-A against 39 without, with no significant difference in ongoing pregnancy or live birth (64.4% against 54%), and another group in which pregnancy rates fell when tested embryos were used; a third reported a 15% aneuploidy rate in donor-egg embryos 3. The numbers are small 3.

Is PGT-A worth the money?

It depends what you are buying. ASRM reports modelling in which cost-effectiveness improves with the woman's age and the number of blastocysts available, and a model in unexplained recurrent pregnancy loss where PGT-A lowered miscarriage (7% against 24%) but not live birth (40% against 55%), and was not cost-effective against simply trying 3. No verifiable Indian price list exists that we could check.

Does PGT-A mean all my embryos have to be frozen?

In practice, yes. The biopsy is taken from a day 5–7 blastocyst and the embryo is usually frozen while the result is awaited 1,2. ESHRE's add-ons group, which does not recommend elective freeze-all for routine use, lists PGT among the clear indications for it 2. So a tested cycle has no fresh transfer, and the first transfer is a frozen one.

How many embryos do you need before PGT-A makes sense?

The trials only enrolled women who already had embryos to spare: STAR required at least two blastocysts suitable for biopsy 4, and the Chinese trial three or more good ones 5. Neither found more babies per cycle 4,5. With a single embryo there is nothing to select between, and the HFEA warns that testing can leave no embryo suitable to transfer 1.

What happens to the embryos that test abnormal?

That follows your clinic's policy, which ASRM says should be written down and disclosed to you before testing, covering aneuploid, mosaic and segmental results 3. In India, an embryo may be stored for no more than ten years, after which it is allowed to perish or, with your consent, donated to a research organisation registered under the Act 14. Ask for that policy in writing.

Sources

  1. Human Fertilisation and Embryology Authority. Pre-implantation genetic testing for aneuploidy (PGT-A) (treatment add-on ratings). HFEA (UK regulator)
  2. ESHRE Add-ons working group; Lundin K, Bentzen JG, Bozdag G, et al. Good practice recommendations on add-ons in reproductive medicine. Hum Reprod. 2023;38(11):2062–2104. ESHRE / Human Reproduction
  3. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. 2024;122(3):421–434. ASRM / SART
  4. Munné S, Kaplan B, Frattarelli JL, et al; STAR Study Group. Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. Fertil Steril. 2019;112(6):1071–1079.e7. Fertility and Sterility
  5. Yan J, Qin Y, Zhao H, et al. Live birth with or without preimplantation genetic testing for aneuploidy. N Engl J Med. 2021;385(22):2047–2058. New England Journal of Medicine
  6. Cornelisse S, Zagers M, Kostova E, Fleischer K, van Wely M, Mastenbroek S. Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation. Cochrane Database Syst Rev. 2020;9:CD005291. Cochrane
  7. ESHRE Working Group on Recurrent Implantation Failure; Cimadomo D, de los Santos MJ, Griesinger G, et al. ESHRE good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023. ESHRE / Human Reproduction Open
  8. Practice Committee of the American Society for Reproductive Medicine. Recurrent implantation failure: a committee opinion. Fertil Steril. 2026;126:277–293. ASRM
  9. Capalbo A, Poli M, Rienzi L, et al. Mosaic human preimplantation embryos and their developmental potential in a prospective, non-selection clinical trial. Am J Hum Genet. 2021;108(12):2238–2247. American Journal of Human Genetics
  10. Viotti M, Victor AR, Barnes FL, et al. Using outcome data from one thousand mosaic embryo transfers to formulate an embryo ranking system for clinical use. Fertil Steril. 2021;115(5):1212–1224. Fertility and Sterility
  11. Rubio C, Bellver J, Rodrigo L, et al. In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study. Fertil Steril. 2017;107(5):1122–1129. Fertility and Sterility
  12. Newnham A, Leeson C, Trunkwala F, Odendaal J, Quenby S. Does preimplantation genetic testing for aneuploidy improve live birth rate in women diagnosed with recurrent implantation failure? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2026;105:575–586. Acta Obstetricia et Gynecologica Scandinavica
  13. ESHRE Guideline Group on RPL; Bender Atik R, Christiansen OB, Elson J, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open. 2023;2023(1):hoad002 (Supplementary Table SI). ESHRE / Human Reproduction Open
  14. The Assisted Reproductive Technology (Regulation) Act, 2021 (Act No. 42 of 2021), Government of India. Sections 25, 26 and 28. Government of India (via PRS Legislative Research)
  15. Franasiak JM, Forman EJ, Hong KH, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril. 2014;101(3):656–663.e1. Fertility and Sterility

Tools for this step

WhatsApp us